Latest American Association for Cancer Research Stories
New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc.
INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies - including bemaciclib "beh meh sye' klib" (LY2835219),
A new study from the University of Pittsburgh Cancer Institute and Magee-Womens Research Institute reveals that genetic screening could someday help clinicians to know which women with endometriosis are most at risk of developing ovarian cancer.
HACKENSACK, N.J., April 4, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development
Women who took clomiphene citrate (brand name Clomid) or gonadotropins as a part of fertility treatment did not experience an increased risk for breast cancer over 30 years of follow-up, compared with women who were not treated with these medications.
HAIFA, Israel, April 3, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that new, pre-clinical data demonstrating the anti-tumor effects of NovoTTF(TM) Therapy will
- Company to Present Data on SF3B1 Program at a Symposium During the American Association for Cancer Research Annual Meeting 2014 - CAMBRIDGE, Mass., April 3, 2014 /PRNewswire/ --
SAN DIEGO and HILDEN, Germany, April 3, 2014 /PRNewswire/ -- - New innovative product launches at American Association for Cancer
New data demonstrates VAL-083 has promise as a potential treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) VANCOUVER, British Columbia
Robust antitumor activity of G1's novel CDK4/6 inhibitors to be highlighted in poster on April 7 CHAPEL HILL, N.C., March 27, 2014 /PRNewswire/ -- G1 Therapeutics, Inc., a privately
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.